Relay Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-83.7M | $-73.3M | $-54.9M | $-74.1M | $-70.4M | $-77.1M | $-76.0M | $-88.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $360.0K | $504.0K | $599.0K | $748.0K | $1.0M | $1.2M | $1.3M | $1.4M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $9.2M | $10.5M | $13.1M | $15.5M | $14.5M | $19.3M | $17.6M | $22.5M |
| Net Cash from Operating Activities | $-54.1M | $-51.1M | $-44.9M | $-62.1M | $-55.3M | $-73.2M | $-57.9M | $-75.1M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $1.0K | $-1.0K | $26.0K | $384.0K | $0 | $227.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-353.0M | $32.9M | $35.5M | $39.7M | $75.1M | $42.5M | $29.0M | $-126.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $323.7M | $138.8M | — | — | — | — | $800.0K | $218.9M |
| Net Change in Cash | $-83.4M | $120.6M | $-8.5M | $-22.4M | $20.5M | $-30.7M | $-28.1M | $17.6M |
| Free Cash Flow | — | — | $-44.9M | $-62.1M | $-55.3M | $-73.6M | $-57.9M | $-75.3M |